ArticleFrontiers in psychiatry2025
Toward precision psychiatry: theoretical implications of bimodal response patterns to vasopressin V1b receptor inhibition in depression.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00358631 (An Eight-Week, Multicenter, Double-Blind, Placebo- and Escitalopram-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Eight-Week, Multicenter, Double-Blind, Placebo- and Escitalopram-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Major Depressive Disorder
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite extensive research and numerous available treatments, major depressive disorder (MDD) remains a significant global health issue with limited efficacy from current monoaminergic antidepressants. Dysfunction in the hypothalamic-pituitary-adrenal (HPA) axis has been implicated in a subgroup of depressed patients, leading to interest in developing targeted treatments such as vasopressin V1b receptor antagonists. Nelivaptan, a potent V1b antagonist, demonstrated statistically significant antidepressant efficacy in one of two previous Phase 2 trials but was not pursued further. Methods: We reanalyzed the trial data (NCT00358631) using a finite mixture of linear regression model (FMM) to investigate whether antidepressant responses to nelivaptan exhibit a bimodal distribution, suggesting distinct responder subgroups. We analyzed the 17-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to day 56 for patients treated with 250 mg BID nelivaptan (n = 62) versus placebo (n = 63). Results: Our analyses revealed a bimodal response distribution exclusively in the nelivaptan-treated group, characterized by two distinct subpopulations: a high-responder subgroup (mean change: -17.14) and a low-responder subgroup (mean change: -3.85). In contrast, the placebo group displayed a unimodal distribution (mean change: -7.06). Discussion: These findings support the hypothesis that nelivaptan effectively reduces depressive symptoms specifically in a subset of MDD patients, potentially identifiable by underlying HPA axis dysfunction. The confirmation of this hypothesis requires further studies integrating measures of HPA axis activity alongside response to nelivaptan treatment, facilitating precision psychiatry approaches for depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.